Scholarlink

<p>Ventilator-associated infections (VAIs) caused by multidrug-resistant (MDR) pathogens poses a significant challenge in intensive care units (ICUs). Phage therapy has emerged as a promising alternative for VAIs, though its efficacy depends on multiple factors. We report a 40-year-old male ICU patient with sequential pulmonary infections of MDR <i>Acinetobacter baumannii</i>, <i>Klebsiella pneumoniae</i>, and <i>Stenotrophomonas maltophilia</i>. Seven rounds of tailored phage therapy—targeting single or dual pathogens—were administered adjunctive to antibiotics. <i>A. baumannii</i> was complete eradication, but <i>K. pneumoniae</i> and <i>S. maltophilia</i> showed cyclical clearance and recurrence due to strain replacement and phage resistance. Phage therapy correlated with reduced bacterial load, fever, procalcitonin, and IL-6 levels, alongside improved pulmonary inflammation, while white blood cell counts and C-reactive protein showed limited response. No severe adverse events occurred. Dynamic shifts in dominant pathogens aligned with clinical progression, with phage therapy providing transient control, extending the window for intervention and reducing high-level antibiotic use. After six months, the patient was weaned from ventilation and discharged. This case underscores the complexity of VAI management and highlights the potential of personalized phage therapy to mitigate MDR infections and minimize antibiotic reliance. This case was enrolled in a single arm trial (ChiCTR2000036801).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Personalized Phage Therapy in an ICU Patient with Polymicrobial Pulmonary Infections: a case from a single-arm trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月27日

查看全文
  • Yongxin Shi,
  • Jie Li,
  • Qian Yang,
  • Jianhui Li,
  • Linlin Li,
  • Jianfang Liu,
  • Jia Dai,
  • Yumeng Shang,
  • Xin Zhou,
  • Lan Yang,
  • Chuanjiang Chen,
  • Ziqi Zhao,
  • Huiqin Zhang,
  • Juan Bao,
  • Tongyu Zhu,
  • Mengjun Cheng,
  • Nannan Wu,
  • He Wang

摘要

Ventilator-associated infections (VAIs) caused by multidrug-resistant (MDR) pathogens poses a significant challenge in intensive care units (ICUs). Phage therapy has emerged as a promising alternative for VAIs, though its efficacy depends on multiple factors. We report a 40-year-old male ICU patient with sequential pulmonary infections of MDR Acinetobacter baumannii, Klebsiella pneumoniae, and Stenotrophomonas maltophilia. Seven rounds of tailored phage therapy—targeting single or dual pathogens—were administered adjunctive to antibiotics. A. baumannii was complete eradication, but K. pneumoniae and S. maltophilia showed cyclical clearance and recurrence due to strain replacement and phage resistance. Phage therapy correlated with reduced bacterial load, fever, procalcitonin, and IL-6 levels, alongside improved pulmonary inflammation, while white blood cell counts and C-reactive protein showed limited response. No severe adverse events occurred. Dynamic shifts in dominant pathogens aligned with clinical progression, with phage therapy providing transient control, extending the window for intervention and reducing high-level antibiotic use. After six months, the patient was weaned from ventilation and discharged. This case underscores the complexity of VAI management and highlights the potential of personalized phage therapy to mitigate MDR infections and minimize antibiotic reliance. This case was enrolled in a single arm trial (ChiCTR2000036801).